nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.07.2009 | Original Paper

Expression of Jun activation domain-binding protein 1 and Ser10 phosphorylated p27 protein in human epithelial ovarian carcinoma

verfasst von: You Wang, Yuchan Wang, Chun Cheng, Yuhong Ji, Yueming Zhao, Lin Zou, Aiguo Shen

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of the present study was to examine whether Jab1 expression is correlated with p27 protein and its phosphorylation status as well as how it might be clinically relevant in epithelial ovarian carcinoma. Using ovarian carcinoma cell line HO-8910 to confirm and extend the findings.

Methods

Immunohistochemical and Western blot analysis were done in 70 cases of epithelial ovarian cacinoma and HO-8910 cells.

Results

Jab1 overexpression was detected in 84.3% (59 of 70) of malignant tumors and 31.6% (6 of 19) of benign tumors. A positive correlation between Jab1 and cytoplasmic p27 as well as Ser10 phosphorylated p27 was found in malignant ovarian tumors. In addition, patients displaying overexpression of Jab1, cytoplasmic p27 and Ser10 phosphorylated p27 were significantly associated with unfavorable clinicopathologic variables. Transfection with Jab1 in HO-8910 cells resulted in decreased p27 expression and this reduction was sensitive to 26S proteasome inhibitors. Overexpression of Jab1 caused p27 nuclear export and dissociate from Cdk2/Cyclin complex. What is more, increased expression of a phosphorylated histone H1 in the immune-complex obtained from Jab1 transfected HO-8910 cells was also observed.

Conclusions

Jab1, as a negative regulator of p27, may be associated with the progression and prognosis of epithelial ovarian tumors.

Chamovitz DA, Segal D (2001) JAB1/CSN5 and the COP9 signalosome. A complex situation. EMBO Rep 2:96–101. doi:10.1093/embo-reports/kve028 PubMedCrossRef

Claret FX, Hibi M, Dhut S et al (1996) A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature 383:453–457. doi:10.1038/383453a0 PubMedCrossRef

D’Andrilli G, Kumar C, Scambia G et al (2004) Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res 10:8132–8141. doi:10.1158/1078-0432.CCR-04-0886 PubMedCrossRef

Ekholm SV, Reed SI (2000) Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 12:676–684. doi:10.1016/S0955-0674(00)00151-4 PubMedCrossRef

Esteva FJ, Sahin AA, Rassidakis GZ et al (2003) Jun activation domain binding protein 1 expression is associated with low p27(Kip1) levels in node-negative breast cancer. Clin Cancer Res 9:5652–5659PubMed

Fero ML, Randel E, Gurley KE et al (1998) The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396:177–180. doi:10.1038/24179 PubMedCrossRef

Guan X, Chen L, Wang J et al (2006) Mutations of phosphorylation sites Ser10 and Thr187 of p27Kip1 abolish cytoplasmic redistribution but do not abrogate G0/1 phase arrest in the HepG2 cell line. Biochem Biophys Res Commun 347:601–607. doi:10.1016/j.bbrc.2006.06.114 PubMedCrossRef

Ishida N, Hara T, Kamura T et al (2002) Phosphotylation of p27kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem 277:14355–14358. doi:10.1074/jbc.C100762200 PubMedCrossRef

Ishida N, Kitagawa M, Hatakeyama S et al (2000) Phosphorylation at serine 10, a major phosphorylation site of p27(Kip1), increases its protein stability. J. Biol. Chem 275:25146–25154PubMedCrossRef

Ozols RF (2002) Update on the management of ovarian cancer. Cancer J 8:S22–S30PubMed

Korbonits M, Chahal HS, Kaltsas G et al (2002) Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab 87:2635–2643. doi:10.1210/jc.87.6.2635 PubMedCrossRef

Kouvaraki MA, Korapati AL, Rassidakis GZ et al (2006) Potential role of Jun activation domain–binding protein 1 as a negative regulator of p27^kip1 in pancreatic adenocarcinoma. Cancer Res 66:8581–8589. doi:10.1158/0008-5472.CAN-06-0975 PubMedCrossRef

Kouvaraki MA, Rassidakis GZ, Tian L et al (2003) Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Res 63:2977–2981PubMed

Lenferink AE, Busse D, Flanagan WM et al (2001) ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res 61:6583–6591PubMed

Liang J, Zubovitz J, Petrocelli T et al (2002) PKB/AKT phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8(10):1153–1160. doi:10.1038/nm761 PubMedCrossRef

Pagano M, Tam SW, Theodoras AM et al (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682–685. doi:10.1126/science.7624798 PubMedCrossRef

Polyak K, Lee MH, Erdjument-Bromage H et al (1994) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 789:59–66. doi:10.1016/0092-8674(94)90572-X CrossRef

Rodier G, Montagnoli A, Marcotullio LD et al (2001) p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 20:6672–6682. doi:10.1093/emboj/20.23.6672 PubMedCrossRef

Schwechheimer C, Deng XW (2001) COP9 signalosome revisited: a novel mediator of protein degradation. Trends Cell Biol 11:420–426. doi:10.1016/S0962-8924(01)02091-8 PubMedCrossRef

Sheaff RJ, Groudine M, Gordon M et al (1997) Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 11:1464–1478. doi:10.1101/gad.11.11.1464 PubMedCrossRef

Sherr CJ (1996) Cancer cell cycles. Science 274:1672–1677. doi:10.1126/science.274.5293.1672 PubMedCrossRef

Shin I, Yakes MF, Rojo F et al (2002) PKB/Akt mediates cell-cycle progression by phosphorylation of p27kip1 at threonine 157 and modulation of its cellular localization. Nat Med 8:1145–1152. doi:10.1038/nm759 PubMedCrossRef

Shintani S, Li C, Mihara M et al (2003) Skp2 and Jab1 expression are associated with inverse expression of p27(KIP1) and poor prognosis in oral squamous cell carcinomas. Oncology 65:355–362. doi:10.1159/000074649 PubMedCrossRef

Slingerland J, Pagano M (2000) Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 183:10–17. doi:10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-IPubMedCrossRef

Sui L, Dong Y, Ohno M et al (2001) Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. Clin Cancer Res 7:4130–4135PubMed

Tomoda K, Kubota Y, Arata Y et al (2002) The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex. J Biol Chem 277:2302–2310. doi:10.1074/jbc.M104431200 PubMedCrossRef

Tomoda K, Kubota Y, Kato J (1999) Degradation of the cyclin-dependentkinase inhibitor p27Kip1 is instigated by Jab1. Nature 398:160–165. doi:10.1038/18230 PubMedCrossRef

Vlach J, Hennecke S, Amati B (1997) Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 16:5334–5344. doi:10.1093/emboj/16.17.5334 PubMedCrossRef

Viglietto G, Motti ML, Bruni P et al (2002) Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 8:1136–1144. doi:10.1038/nm762 PubMedCrossRef

Titel: Expression of Jun activation domain-binding protein 1 and Ser10 phosphorylated p27 protein in human epithelial ovarian carcinoma
verfasst von: You Wang
Yuchan Wang
Chun Cheng
Yuhong Ji
Yueming Zhao
Lin Zou
Aiguo Shen
Publikationsdatum: 01.07.2009
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 7/2009
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-008-0531-y

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Expression of Jun activation domain-binding protein 1 and Ser10 phosphorylated p27 protein in human epithelial ovarian carcinoma

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2009

WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions

Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death

Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI

Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel

Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer

High-efficiency transfer and expression of AdCMV-p53 in human cervix adenocarcinoma cells induced by subclinical-dose carbon beam radiation

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie